146 related articles for article (PubMed ID: 8439507)
1. Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma.
Coombs LM; Pigott DA; Eydmann ME; Proctor AJ; Knowles MA
Br J Cancer; 1993 Mar; 67(3):578-84. PubMed ID: 8439507
[TBL] [Abstract][Full Text] [Related]
2. Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas.
Eder IE; Stenzl A; Hobisch A; Cronauer MV; Bartsch G; Klocker H
Br J Cancer; 1997; 75(12):1753-60. PubMed ID: 9192977
[TBL] [Abstract][Full Text] [Related]
3. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder.
Coombs LM; Pigott DA; Sweeney E; Proctor AJ; Eydmann ME; Parkinson C; Knowles MA
Br J Cancer; 1991 Apr; 63(4):601-8. PubMed ID: 1673627
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder.
Kim JH; Shariat SF; Kim IY; Menesses-Diaz A; Tokunaga H; Wheeler TM; Lerner SP
Cancer; 2001 Sep; 92(6):1475-83. PubMed ID: 11745225
[TBL] [Abstract][Full Text] [Related]
5. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
King ED; Matteson J; Jacobs SC; Kyprianou N
J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
[TBL] [Abstract][Full Text] [Related]
6. Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors.
Xu Y; See WA
Surg Oncol; 1994 Jun; 3(3):175-85. PubMed ID: 7952402
[TBL] [Abstract][Full Text] [Related]
7. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
Buchumensky V; Klein A; Zemer R; Kessler OJ; Zimlichman S; Nissenkorn I
J Urol; 1998 Dec; 160(6 Pt 1):1971-4. PubMed ID: 9817302
[TBL] [Abstract][Full Text] [Related]
9. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
10. Expression of transforming growth factor-beta 1 in human bladder cancer.
Miyamoto H; Kubota Y; Shuin T; Torigoe S; Dobashi Y; Hosaka M
Cancer; 1995 May; 75(10):2565-70. PubMed ID: 7736402
[TBL] [Abstract][Full Text] [Related]
11. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression.
Soini Y; Turpeenniemi-Hujanen T; Kamel D; Autio-Harmainen H; Risteli J; Risteli L; Nuorva K; Pääkkö P; Vähäkangas K
Br J Cancer; 1993 Nov; 68(5):1029-35. PubMed ID: 8217593
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
[TBL] [Abstract][Full Text] [Related]
13. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.
Berndt A; Anger K; Richter P; Borsi L; Brack S; Silacci M; Franz M; Wunderlich H; Gajda M; Zardi L; Neri D; Kosmehl H
J Cancer Res Clin Oncol; 2006 Aug; 132(8):537-46. PubMed ID: 16788848
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas.
Kömhoff M; Guan Y; Shappell HW; Davis L; Jack G; Shyr Y; Koch MO; Shappell SB; Breyer MD
Am J Pathol; 2000 Jul; 157(1):29-35. PubMed ID: 10880372
[TBL] [Abstract][Full Text] [Related]
16. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma.
Zhang G; Cao Y; Xu Y; See WA
Urol Oncol; 2005; 23(6):413-8. PubMed ID: 16301119
[TBL] [Abstract][Full Text] [Related]
17. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas.
Franchi A; Arganini L; Baroni G; Calzolari A; Capanna R; Campanacci D; Caldora P; Masi L; Brandi ML; Zampi G
J Pathol; 1998 Jul; 185(3):284-9. PubMed ID: 9771482
[TBL] [Abstract][Full Text] [Related]
18. Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay.
Clifford SC; Thomas DJ; Neal DE; Lunec J
Br J Cancer; 1994 Apr; 69(4):680-6. PubMed ID: 7908215
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
20. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.
Pignot G; Bieche I; Vacher S; Güet C; Vieillefond A; Debré B; Lidereau R; Amsellem-Ouazana D
Eur Urol; 2009 Oct; 56(4):678-88. PubMed ID: 18513850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
